Lentivirus Manufacturing Process for Primary T-Cell Biofactory Production.

Area of Science:

• Biotechnology
• Cellular Engineering
• Gene Therapy

Background:

• Lentivirus particles are crucial for transducing primary cells, but maximizing their titer is essential for therapeutic applications.
• Engineering primary T cells as 'biofactories' or chimeric antigen receptor (CAR) T cells requires efficient lentiviral vector production.

Purpose of the Study:

• To develop and optimize a process for maximizing lentivirus particle titer.
• To engineer primary T cells into T-cell biofactories for protein synthesis and CAR T cells for targeted therapy.
• To validate the functionality of engineered T cells and ensure the process is scalable and compliant with Good Manufacturing Practices (GMP).

Main Methods:

• Development of a novel process to enhance lentivirus particle production.
• Transduction of primary T cells using lentivirus vectors encoding artificial cell-signaling pathways (for biofactories) or antigen-specific chimeric antigen receptors (for CAR T cells).
• Expansion and functional validation of engineered T cells, including protein synthesis and cytolytic activity.

Main Results:

• Successful maximization of lentivirus particle titer.
• Generation of functional T-cell biofactories capable of calibrated protein synthesis.
• Generation of functional CAR T cells exhibiting target cell cytolysis.
• Demonstration of process compliance with current Good Manufacturing Practices (GMP).

Conclusions:

• The developed process effectively maximizes lentivirus production, enabling the generation of engineered primary T cells for therapeutic purposes.
• The engineered T cells (biofactories and CAR T cells) exhibit validated functions crucial for potential clinical translation.
• The GMP-compliant process supports the scale-up necessary for clinical applications in gene therapy and immunotherapy.